In short
Clinical trials are investigating VOXVOGANAN in people with COVID-19 and COVID-like illness in primary care. These studies aim to evaluate recovery time, viral clearance, and other measures of illness severity. The trial is a phase 4 interventional study with a large target population.
Key points
- Clinical trials are studying VOXVOGANAN in people with COVID-19 and COVID-like illness in primary care. The available trial is an authorised phase 4 interventional study with 1201 planned participants. The main goals are to measure how quickly people feel recovered and whether the virus clears from the body. The trial also looks at viral load and markers of illness severity or immune response. One part of the study compares viral clearance at Day 3 against placebo. The source data do not give full participant rules, but the study is focused on people with these respiratory illnesses.
Clinical trials overview
The available trial for VOXVOGANAN is an interventional study, which means researchers give a study treatment or comparison product and then measure the results. It is studying people with COVID-19 and COVID-like illness in primary care.
The study status is Authorised, and the planned enrollment is 1201 people. The trial title shows that it is focused on treatment in the primary care setting.
Who is being studied
The target population is people with COVID-19 or COVID-like illness. The source data do not list the full inclusion or exclusion rules, so the exact participation criteria are not available here.
The study is set in primary care, which usually means routine first-contact health care rather than hospital care. This suggests the trial is looking at people who are being managed outside the hospital.
Study design and phase
This is a Phase 4 trial. Phase 4 studies are later-stage trials that look at a treatment in a broader real-world type setting after earlier research has already happened.
The brief summary says the platform study is phase dependent, meaning the main goal can change depending on the part of the study or intervention-specific appendix. For the main protocol, the trial aims to compare the study product with usual care or with a comparator such as placebo.
What the trials measure
One main outcome is the time to first self-report of feeling recovered from symptoms related to COVID-19 or COVID-like illness. This means the study asks when a person first says they feel recovered.
The trial also measures viral clearance, which means whether the virus is gone or much lower in the body, and may also measure viral load, which is the amount of virus present. In addition, the study may look at biomarkers, which are body measurements that can show illness severity or immune response.
For one part of the study, called ISA D, the primary objective is viral clearance by VOXVOGANAN measured at Day 3 after inclusion compared with placebo. The source data also mention a phase IIa-type evaluation for viral clearance, viral load, and biomarkers, and a phase IIb/III-type evaluation for time to recovery.
Study comparators and treatment groups
The trial compares the study treatment with usual care or with a comparator, such as placebo or another study product. A placebo is a look-alike product without the active substance, used to make the comparison fair.
The intervention list includes VOXVOGANAN, nitric oxide nasal spray, saline nasal spray, and placebo nasal sprays. The source data do not explain the full role of each product in this summary, but they show that different nasal spray options are part of the platform study.
What the data do not say
The source data do not provide detailed participant rules, such as age limits, lab requirements, or symptom duration. They also do not give detailed results, so this article focuses on the study goals and design rather than outcomes.
The data available here describe one authorised trial and its main endpoints, but they do not include a full list of all related studies.